about
Hematopoietic growth factor inducible neurokinin-1 type: a transmembrane protein that is similar to neurokinin 1 interacts with substance PThe neuronal cyclin-dependent kinase 5 activator p35Nck5a and Cdk5 activity in monocytic cellsMimicry between neurokinin-1 and fibronectin may explain the transport and stability of increased substance P immunoreactivity in patients with bone marrow fibrosis.The rationale for deltanoids in therapy for myeloid leukemia: role of KSR-MAPK-C/EBP pathway.Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and up-regulates p27Kip1 concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D(3).ERK5 pathway regulates transcription factors important for monocytic differentiation of human myeloid leukemia cells.The MAPK ERK5, but not ERK1/2, inhibits the progression of monocytic phenotype to the functioning macrophage.The pan-caspase inhibitor Q-VD-OPh has anti-leukemia effects and can interact with vitamin D analogs to increase HPK1 signaling in AML cells.c-Jun N-terminal kinase 2 (JNK2) antagonizes the signaling of differentiation by JNK1 in human myeloid leukemia cells resistant to vitamin DERK 5/MAPK pathway has a major role in 1α,25-(OH)2 vitamin D3-induced terminal differentiation of myeloid leukemia cells.Vitamin D Control of Hematopoietic Cell Differentiation and Leukemia.BRAF signals to pro-apoptotic BIM to enhance AraC cytotoxicity induced in AML cells by Vitamin D-based differentiation agents.The role of VDR and BIM in potentiation of cytarabine-induced cell death in human AML blasts.Translational study of vitamin D differentiation therapy of myeloid leukemia: effects of the combination with a p38 MAPK inhibitor and an antioxidant.Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.Nuclear factor-kappaB modulation in patients undergoing induction chemotherapy for acute myelogenous leukemia.JNK1 as a signaling node in VDR-BRAF induction of cell death in AML.Left ventricular non-Hodgkin lymphoma visualized on contrast echocardiography.Evidence of both von Willebrand factor deposition and factor V deposition onto AL amyloid as the cause of a severe bleeding diathesis.Peripheral monocytes and CD4+ cells are potential sources for increased circulating levels of TGF-beta and substance P in autoimmune myelofibrosis.Large granular lymphocytic leukemia complicating autoimmune polyglandular syndrome type 1 in siblings.Simultaneous appearance of trisomy 8 and trisomy 12 in different cell populations in a patient with untreated B-cell chronic lymphocytic leukemia and myelodysplasiaCure of glioma: a space not yet occupied for the lesionStomatocytosis heralding a case of acute Wilsonian crisisParticipation of vitamin D-upregulated protein 1 (TXNIP)-ASK1-JNK1 signalosome in the enhancement of AML cell death by a post-cytotoxic differentiation regimenPrimary central nervous system marginal zone B-cell lymphoma arising from the dural meninges: A case report and review of literature
P50
Q28116055-4708515E-A01F-47AC-A092-9F98371D9D3AQ28190225-77BB6499-62AC-477B-9473-53C8CE21B7ABQ30666991-D3861080-E1ED-421E-90A5-CBE13722C636Q33622877-7786EAE0-350B-4BBD-8287-5436F3ACC28CQ34620898-598A8363-B8C4-423B-9868-92A6011C7089Q35189239-A68D2CC1-4057-4DC1-BEB4-8AEFD0DE32BEQ35189282-462A7E10-081E-4176-A3D3-7AC3548433D6Q35992449-C3EFBB9B-801B-4B96-8765-2BCE8235AFE2Q37252079-E9389C6B-7093-4C74-9585-3A28CBE78E57Q37724276-4B81D014-C084-43E0-8FEA-D695ADAEC186Q39037456-99DFEC07-DA5E-4A73-9691-D91D0C689E8AQ39381021-CF6B5813-FBE3-447C-A73C-FB687DEA8903Q39796064-E95E092C-750E-4A0B-8854-F0CA8B983952Q40383903-4D30C414-E57D-4AFA-A204-6198E9578857Q42502979-2C6CC6D0-4DA3-4B65-B76F-438DAD28A17AQ42598206-41E06446-BA48-4379-B27F-C54C6CDE2E11Q44637210-EB6AC60A-C47D-4459-B95A-58828968C601Q46245225-82DA0B6D-0187-4B48-BFA2-EA8741811EA9Q48706475-1905F995-0FA4-4FED-8E43-89A3A4EC7D0AQ51042905-641488E2-FEE1-4EBA-91BF-4405353DC8BDQ51456458-E35193E3-2563-41D6-9384-5D229BF59F5EQ53643306-885001A4-33B5-47B7-9799-4294DFFAC235Q55259107-96125CFF-DBB9-4B5D-B67C-A4607734AE57Q80549109-0C3BDC2F-B95D-4722-9AF4-39BC90FA30A1Q80881954-593C329B-73B3-4B8C-8FFF-8261FFF4D7A9Q84583791-2F5E2142-4247-4324-97C7-10373135A96CQ90218021-EF3C546F-0D61-4363-AAA3-E589574F91EEQ90413346-FC7A5DF5-663A-4BD4-B710-8E85EFD7CDFD
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jonathan S Harrison
@nl
Jonathan S Harrison
@sl
Jonathan S. Harrison
@en
Jonathan S. Harrison
@es
type
label
Jonathan S Harrison
@nl
Jonathan S Harrison
@sl
Jonathan S. Harrison
@en
Jonathan S. Harrison
@es
prefLabel
Jonathan S Harrison
@nl
Jonathan S Harrison
@sl
Jonathan S. Harrison
@en
Jonathan S. Harrison
@es
P106
P1153
57191290908
7402742732
P21
P31
P496
0000-0002-5815-709X